IFNA1 and hepatocellular carcinoma: In this respect, with interferon (IFN)-based therapies, achieving with interferon (IFN)-based therapies sustained virologic response (SVR), i.e., undetectable HCV-RNA at 12–24 weeks after completion of treatment, reduces the incidence of HCC.